Policy Notices

• Updated Policy on SBIR/STTR Organization Eligibility in Cases of Legal Action that Changes Small Business Status
  (NOT-OD-22-143)
  National Institutes of Health
  

General Notices

• Notice of Joint NSF/NIGMS Initiative to Support Research at the Interface of the Biological and Mathematical Sciences
  (NOT-GM-22-039)
  National Institute of General Medical Sciences
  

• Correction to NOT-HG-22-014: Solicitation of Nominations for the 2022 National Human Genome Research Institutes Outstanding Award for Enhancing Diversity, Equity, Inclusion, and Accessibility in the Genomics Workforce
  (NOT-HG-22-029)
  National Human Genome Research Institute
  

• Notice of NHLBI Participation in NOT-OD-22-140 "Notice of Special Interest: Administrative Supplement for Research Efforts that Illuminate Fundamental Processes Underlying Behavior Change, Maintenance, and Adherence" (Admin Supp Clinical Trial Optional)
  (NOT-HL-22-029)
  National Heart, Lung, and Blood Institute
  

• NIH Announces the Open Period of FY 2023 Helium-3 Requests for Medical Research
  (NOT-HL-22-032)
  National Heart, Lung, and Blood Institute
  

• Notice of NHLBI Participation in NOT-OD-22-141 "Notice of Special Interest: Administrative Supplements to NIH-funded T32 and TL1 Training Grants to Better Integrate Behavioral and Social Sciences (BSS) with other Health-Related Sciences"
  (NOT-HL-22-033)
  National Heart, Lung, and Blood Institute
  

• Notice of Correction to NOT-OD-22-109 - Inviting Comments and Suggestions on the Development of a Prize Competition for Institutional Excellence in Diversity, Equity, Inclusion, and Accessibility.
  (NOT-OD-22-147)
  Office of the Director, NIH
  

Notice of Changes to Funding Opportunities

• Notice of Correction to Salary Amounts for RFA-AG-23-016, "Transition to Aging Research for Predoctoral Students (F99/K00 Clinical Trial Not Allowed)
  (NOT-AG-22-026)
  National Institute on Aging
  

• Notice of Correction to RFA-CA-22-022, "Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)"
  (NOT-CA-22-090)
  National Cancer Institute
  

• Notice to Extend Expiration Date for PAR-20-277: Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Clinical Trial Not Allowed)
  (NOT-CA-22-093)
  National Cancer Institute
  National Institute of Dental and Craniofacial Research
  

• Notice of NCI's Participation in Notice of Special Interest: Administrative Supplement for Research Efforts that Illuminate Fundamental Processes Underlying Behavior Change, Maintenance, and Adherence (Admin Supp Clinical Trial Optional)
  (NOT-CA-22-101)
  National Cancer Institute
  

• Notice of NIDA's Participation in NOT-EB-22-001, " Notice of Intent to Publish a Funding Opportunity Announcement for Point-of-Care Technologies Research Network Centers (U54 Clinical Trial Optional)"
  (NOT-DA-22-069)
  National Institute on Drug Abuse
  

• Notice of Change of Application Due Date and Application Types Allowed for RFA-ES-22-004 "SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)"
  (NOT-ES-22-012)
  National Institute of Environmental Health Sciences
  

• Notice of Expiration of RFA-HL-21-013 "Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required)"
  (NOT-HL-22-031)
  National Heart, Lung, and Blood Institute
  

• Notice to Extend RFA-MH-21-180, BRAIN Initiative: Reagent Resources for Brain Cell Type-Specific Access and Manipulation to Broaden Distribution of Enabling Technologies for Neuroscience (U24 Clinical Trial Not Allowed)
  (NOT-MH-22-250)
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Neurological Disorders and Stroke
  

• Notice of NINR Participation in NOT-OD-22-140, Notice of Special Interest (NOSI): Administrative Supplement for Research Efforts that Illuminate Fundamental Processes Underlying Behavior Change, Maintenance, and Adherence (Admin Supp)
  (NOT-NR-22-014)
  National Institute of Nursing Research
  

• Notice of Corrected Application Forms and Extended Receipt Date for PAR-22-076 "Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)"
  (NOT-NS-22-110)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Additional Information for Funding Opportunity RFA-RM-22-020, NIH Directors Transformative Research Awards (R01 Clinical Trial Optional)
  (NOT-RM-22-017)
  Office of Strategic Coordination (Common Fund)
  

• Notice of Change to PD(s/PI(s) Eligibility Requirements and Addition of Letter of Intent Deadline for PAR-19-362 Planning Grant for Global Infectious Disease Research Training Program (D71 - Clinical Trials Not Allowed)
  (NOT-TW-22-004)
  John E. Fogarty International Center
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 Clinical Trial Not Allowed)
  (NOT-CA-22-088)
  National Cancer Institute
  

• Notice of Intent to Publish a Funding Opportunity Announcement for NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
  (NOT-CA-22-094)
  National Cancer Institute
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed)
  (NOT-DA-22-070)
  National Institute on Drug Abuse
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Centers for Oceans and Human Health 4: Impacts of Climate Change on Oceans and Great Lakes (COHH4) (P01 Clinal Trial Optional)
  (NOT-ES-22-011)
  National Institutes of Health
  National Institute of Environmental Health Sciences
  

• Notice of Intent to Publish the Reissuance of RFA-OD-20-008, Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Not Allowed)
  (NOT-OD-22-081)
  Office of Disease Prevention
  National Cancer Institute
  National Heart, Lung, and Blood Institute
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  

• Notice of Intent to Publish the Reissuance of RFA-OD-20-011, Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required)
  (NOT-OD-22-082)
  Office of Disease Prevention
  National Cancer Institute
  National Heart, Lung, and Blood Institute
  National Institute on Drug Abuse
  

• Notice of Intent to Publish the Reissuance of RFA-OD-20-009, Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Not Allowed)
  (NOT-OD-22-083)
  Office of Disease Prevention
  National Cancer Institute
  National Heart, Lung, and Blood Institute
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  

• Notice of Intent to Publish the Reissuance of RFA-OD-20-010, Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required)
  (NOT-OD-22-084)
  Office of Disease Prevention
  National Cancer Institute
  National Heart, Lung, and Blood Institute
  National Institute on Drug Abuse
  

Notices of Special Interest

• Notice of Special Interest (NOSI): Research to Support Regulatory Science on Infant Formula
  (NOT-HD-22-016)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Office of the Director, NIH
  Office of Dietary Supplements
  

• Notice of Special Interest (NOSI): Preventive Interventions to Address Cardiometabolic Risk Factors in Populations that Experience Health Disparities
  (NOT-OD-22-154)
  Office of Disease Prevention
  National Cancer Institute
  National Heart, Lung, and Blood Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Dental and Craniofacial Research
  National Institute of Environmental Health Sciences
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  Office of Behavioral and Social Sciences Research
  Office of Research on Women's Health
  

Funding Opportunities

• Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)
  (PAR-22-164)
  National Cancer Institute
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)
  (PAR-22-165)
  National Cancer Institute
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)
  (PAR-22-198)
  National Cancer Institute
  Application Receipt Date(s): September 07, 2025
  
  

• Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional)
  (PAR-22-199)
  National Cancer Institute
  Application Receipt Date(s): September 07, 2025
  
  

• Network for Personalization of Diagnostic Tests for Alzheimers Disease (AD) and Alzheimers Disease-Related Dementias (ADRD) in Older Adults with Multiple Chronic Conditions (MCCs) (U24 Clinical Trial Optional)
  (RFA-AG-23-032)
  National Institute on Aging
  Application Receipt Date(s): October 17, 2022
  
  

• Limited Competition: A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research (U24 Clinical Trial Not Allowed)
  (RFA-CA-22-026)
  National Cancer Institute
  National Heart, Lung, and Blood Institute
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): September 15, 2022
  
  

• Registry of Medical Cannabis Use and Health Outcomes (UM1 - Clinical Trial Optional)
  (RFA-DA-23-011)
  National Institute on Drug Abuse
  Application Receipt Date(s): November 15, 2022
  
  

• Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 Clinical Trial Not Allowed)
  (RFA-DA-23-052)
  National Institute on Drug Abuse
  Application Receipt Date(s): August 10, 2022
  
  

• Pragmatic Clinical Trials in Community Settings to Decrease or Prevent VCID Outcomes, Including in Populations that Experience Health Disparities (U01 Clinical Trial Required)
  (RFA-NS-23-001)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  Application Receipt Date(s): September 15, 2022